Peter Shields MD

Peter Shields MD
ProfessorCollege of Medicineshields.167@osu.edu
519 James Cancer Hosp & Res Inst 300 W 10th Avenue Columbus Ohio 43210
Phone:614-688-6563Fax:
  • Cancer Control
  • Administrative

Research Description

Dr. Shields' focus of research is on the development of phenotypes and gene-environment interactions for cancer risk, focusing on both breast cancer risk and the other on tobacco-related harm. Major initiatives, grant projects and contracts that Dr. Shields has directed included a multi-institution contract from the National Cancer Institute directed towards developing new methods to study tobacco products. He also led a Department of Defense Breast Cancer Center of Excellence to understand why alcohol drinking causes breast cancer, and is used as a paradigm for cancer risk relating to nutrition.

Current Publications

  • Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JCValidation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.Blood 124 42-8 7/3/2014
  • Mathé EA, Patterson AD, Haznadar M, Manna SK, Krausz KW, Bowman ED, Shields PG, Idle JR, Smith PB, Anami K, Kazandjian DG, Hatzakis E, Gonzalez FJ, Harris CCNoninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer.Cancer Res 74 3259-70 6/15/2014
  • Llanos AA, Brasky TM, Mathew J, Makambi KH, Marian C, Dumitrescu RG, Freudenheim JL, Shields PGGenetic Variation in Adipokine Genes and Associations with Adiponectin and Leptin Concentrations in Plasma and Breast Tissue.Cancer Epidemiol Biomarkers Prev in press 5/13/2014
  • Kimbrough RD, Krouskas CA, Xu W, Shields PGMortality among capacitor workers exposed to polychlorinated biphenyls (PCBs), a long-term update.Int Arch Occup Environ Health in press 4/22/2014
  • Nelson DE, Faupel-Badger J, Phillips S, Belcher B, Chang S, Abrams DB, Kramer BS, White MC, O'Malley M, Varanasi AP, Fabian CJ, Wiest JS, Colditz GA, Hall K, Shields PG, Weitzel JNFuture directions for postdoctoral training in cancer prevention: insights from a panel of experts.Cancer Epidemiol Biomarkers Prev 23 679-83 4/1/2014
  • Ambrosone CB, Young AC, Sucheston LE, Wang D, Yan L, Liu S, Tang L, Hu Q, Freudenheim JL, Shields PG, Morrison CD, Demissie K, Higgins MJGenome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry.Oncotarget 5 237-48 1/15/2014
  • Tao MH, Hainaut P, Marian C, Nie J, Ambrosone C, Edge SB, Trevisan M, Dorn J, Shields PG, Freudenheim JLAssociation of prediagnostic physical activity with survival following breast cancer diagnosis: influence of TP53 mutation status.Cancer Causes Control 24 2177-86 12/1/2013
  • Brasky TM, Li Y, Jaworowicz DJ, Potischman N, Ambrosone CB, Hutson AD, Nie J, Shields PG, Trevisan M, Rudra CB, Edge SB, Freudenheim JLPregnancy-related characteristics and breast cancer risk.Cancer Causes Control 24 1675-85 9/1/2013
  • Graves KD, Leventhal KG, Nusbaum R, Salehizadeh Y, Hooker GW, Peshkin BN, Butrick M, Tuong W, Mathew J, Goerlitz D, Fishman MB, Shields PG, Schwartz MDBehavioral and psychosocial responses to genomic testing for colorectal cancer risk.Genomics 102 123-30 8/1/2013
  • Ricks-Santi LJ, Nie J, Marian C, Ochs-Balcom HM, Trevisan M, Edge SB, Kanaan Y, Freudenheim JL, Shields PGBRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study.Genet Epidemiol 37 504-11 7/1/2013
  • Llanos AA, Brasky TM, Dumitrescu RG, Marian C, Makambi KH, Kallakury BV, Spear SL, Perry DJ, Convit RJ, Platek ME, Adams-Campbell LL, Freudenheim JL, Shields PGPlasma IGF-1 and IGFBP-3 may be imprecise surrogates for breast concentrations: an analysis of healthy women.Breast Cancer Res Treat 138 571-9 4/1/2013
  • Luta G, Ford MB, Bondy M, Shields PG, Stamey JDBayesian sensitivity analysis methods to evaluate bias due to misclassification and missing data using informative priors and external validation data.Cancer Epidemiol 37 121-6 4/1/2013
  • Han D, Nie J, Bonner MR, Ambrosone C, Marian C, Shields P, Trevisan M, Edge SB, Freudenheim JLClustering of place of birth for women with breast cancer: differences by tumor characteristics.Cancer Causes Control 24 587-94 3/1/2013
  • Nusbaum R, Leventhal KG, Hooker GW, Peshkin BN, Butrick M, Salehizadeh Y, Tuong W, Eggly S, Mathew J, Goerlitz D, Shields PG, Schwartz MD, Graves KDTranslational Genomic Research: Protocol Development and Initial Outcomes following SNP Testing for Colon Cancer Risk.Transl Behav Med 3 17-29 3/1/2013
  • Hsu PC, Zhou B, Zhao Y, Ressom HW, Cheema AK, Pickworth W, Shields PGFeasibility of identifying the tobacco-related global metabolome in blood by UPLC-QTOF-MS.J Proteome Res 12 679-91 2/1/2013
  • Llanos AA, Dumitrescu RG, Marian C, Makambi KH, Spear SL, Kallakury BV, Perry DJ, Convit RJ, Platek ME, Millen AE, Adams-Campbell LL, Freudenheim JL, Shields PGAdipokines in plasma and breast tissues: associations with breast cancer risk factors.Cancer Epidemiol Biomarkers Prev 21 1745-55 10/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu